JNJ · Johnson & Johnson

Healthcare NYQ United States jnj.com ↗
Val Gro Qua Mom Sta Cap P/S6.54 P/E Fwd P/E21.33 PEG4.26 52W –  RSI Target$277.91 (+4.6%) Beta0.23 Div1.97%
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Drug Manufacturers - General New Brunswick, United States 138,200 employees
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 48 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
9Bullish
5Bearish
0Neutral

Key Signals 1

▲ Double Bottom Major reversal 2026-06-25 · $241.6
Two lows ~$224.17 — bullish reversal confirmed
Learn more →

Momentum Signals 13

▲ MACD Bullish Crossover 2026-05-13 · $229.1
▲ MACD Bullish Crossover 2026-06-05 · $232.77
▲ MACD Bullish Crossover 2026-06-23 · $239.08
▲ Bull Flag 2026-07-07 · $263.1

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Oct 13, 2026
Beat Rate 100%
Consensus BUY
Analyst Upside +4.6%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
16
6
1
BuyHoldSell
Price Target Range
$277.91 +4.6% upside
Low $190 High $320
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 68.14%Last 12 Months
Operating Margin 29.19%Last 12 Months
Return on Equity 25.74%Last 12 Months
Revenue Growth 6.60%Year over Year
Free Cash Flow 16.89BLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 57.71Most Recent Quarter
Current Ratio 1.09Most Recent Quarter
Cash 20.76BMost Recent Quarter
Total Debt 49.04BMost Recent Quarter
Net Debt Most Recent Quarter
How JNJ Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap640.02B
Enterprise Value668.30B
Trailing P/E30.88
Forward P/E21.33
PEG Ratio (5yr)4.26
Price/Sales (ttm)6.54
Price/Book (mrq)7.53
EV/Revenue6.82
EV/EBITDA19.16
Share Statistics
Avg Vol (3m)7.74M
Shares Outstanding2.41B
Float2.41B
% Held by Insiders0.05%
% Held by Institutions76.73%
Short Ratio3.32
Short % of Float1.00%
Profitability
Gross Margin68.14%
Operating Margin (ttm)29.19%
Profit Margin21.48%
Return on Assets (ttm)8.60%
Return on Equity (ttm)25.74%
Income Statement
Revenue (ttm)97.93B
Revenue Growth (yoy)6.60%
Gross Profit (ttm)66.73B
EBITDA34.87B
Net Income (ttm)21.04B
Diluted EPS (ttm)8.60
EPS Growth (yoy)-0.90%
Balance Sheet
Total Cash (mrq)20.76B
Total Debt (mrq)49.04B
Debt / Equity (mrq)57.71
Current Ratio (mrq)1.09
Book Value / Share35.28
Operating CF (ttm)27.61B
Free Cash Flow (ttm)16.89B
Trading & Dividends
Beta (5Y)0.23
50-Day MA262.48
200-Day MA236.81
Fwd Dividend Yield2.01%
Payout Ratio60.79%
Income
Dividend Yield 1.97%Last 12 Months
Annual Rate 5.36Forward
Payout Ratio 60.79%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 60.79%
Monthly Dividends
Ownership Breakdown
Institutional 76.73% Insider 0.05% Public 23.2%
Short Interest 1.00% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in JNJ in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value